id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-1214-0034,FDA,FDA-2021-D-1214,Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry,Other,Guidance,2023-08-31T04:00:00Z,2023,8,2023-08-31T04:00:00Z,,2024-11-12T23:54:03Z,,1,0,0900006485f204e0
FDA-2021-D-1214-0033,FDA,FDA-2021-D-1214,"Considerations for the Use of Real- World Data and Real-World Evidence
To Support Regulatory Decision- Making for Drug and Biological
Products; Guidance for Industry; Availability",Notice,Guidance,2023-08-31T04:00:00Z,2023,8,2023-08-31T04:00:00Z,,2023-08-31T14:27:07Z,2023-18841,0,0,0900006485f1edb3
FDA-2021-D-1214-0001,FDA,FDA-2021-D-1214,"Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry;
Availability",Notice,Notice of Availability,2021-12-09T05:00:00Z,2021,12,2021-12-09T05:00:00Z,2022-03-10T04:59:59Z,2024-11-07T00:34:19Z,2021-26640,1,0,0900006484eb23b7
FDA-2021-D-1214-0002,FDA,FDA-2021-D-1214,Draft Guidance - Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products,Other,Guidance,2021-12-09T05:00:00Z,2021,12,2021-12-09T05:00:00Z,,2021-12-09T15:55:55Z,,0,0,0900006484eb3028